ArticleAnnals of the rheumatic diseases2022

Response to: 'Effectiveness and safety of ruxolitinib for the treatment of refractory systemic idiopathic juvenile arthritis like associated with interstitial lung disease: case report' by Bader-Meunier

Vivian E Saper et al.PubMed ↗Publisher ↗

No numbers read from the abstract.